Gaboxadol (THIP): GABA-A Agonist for Neuroscience Research
Gaboxadol (THIP): GABA-A Agonist for Neuroscience Research
Gaboxadol(THIP) is a potent, selective agonist at extrasynaptic GABA-A receptors containing the δ subunit, making it an important pharmacological tool for studying tonic inhibition, sleep regulation, and neurological disorders.
- Chemical Name
- 4,5,6,7-Tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP)
- Molecular Formula
- C₅H₈N₂O₂
- Molecular Weight
- 128.13 g/mol
- Primary Target
- Extrasynaptic GABA-A receptors (δ-subunit containing)
- Mechanism
- Selective agonist at δ-subunit-containing GABA-A receptors; mediates tonic inhibition
- Key Research Applications
- Sleep studies, anesthesia research, anxiety and epilepsy models, Angelman syndrome research
What Is Gaboxadol (THIP)?
Gaboxadol, also known by its chemical abbreviation THIP (4,5,6,7-Tetrahydroisoxazolo[5,4-c]pyridin-3-ol), is a synthetic muscimol analogue originally developed as a potential analgesic and anxiolytic agent. It is a selective, direct agonist at γ-aminobutyric acid type A (GABA-A) receptors, particularly those located at extrasynaptic sites and containing the δ subunit. Unlike classical benzodiazepines, which act as positive allosteric modulators requiring endogenous GABA, gaboxadol directly activates the receptor channel, producing robust tonic inhibition in target neurons.
Gaboxadol entered clinical development as a hypnotic agent under the trade name Lunesta competitor Gaboxadol, but clinical trials were ultimately discontinued due to adverse effects at higher doses. Despite this, gaboxadol remains a highly valuable pharmacological research tool for dissecting the roles of extrasynaptic GABA-A receptors in the central nervous system.
Mechanism of Action and Receptor Pharmacology
GABA-A receptors are ligand-gated ion channels that, upon activation, allow chloride ions to flow into the neuron, thereby hyperpolarizing the cell and reducing neuronal excitability. These receptors exist in two functional pools: synaptic receptors, which mediate rapid phasic inhibition in response to synaptically released GABA, and extrasynaptic receptors, which are continuously exposed to low ambient GABA concentrations and generate a sustained tonic inhibitory current.
Gaboxadol preferentially activates extrasynaptic GABA-A receptors containing the δ subunit, commonly assembled with α4 or α6 subunits. These receptor subtypes exhibit high affinity for GABA and do not desensitize readily, making them ideal mediators of tonic inhibition. By selectively engaging this population, gaboxadol allows researchers to pharmacologically isolate and study tonic inhibitory conductances without substantially interfering with phasic synaptic transmission.
At higher concentrations, gaboxadol can also activate synaptic GABA-A receptor subtypes, so careful dose selection is essential in experimental design to maintain selectivity for extrasynaptic receptors.
Research Applications
Sleep and Circadian Research: Gaboxadol has been extensively used to study the neurobiology of sleep. Because δ-subunit-containing GABA-A receptors are highly expressed in brain regions involved in sleep regulation, including the thalamus and cortex, gaboxadol reliably promotes slow-wave sleep (SWS) in animal models. It is employed to dissect the contributions of tonic GABAergic inhibition to sleep architecture and to model pharmacologically induced slow-wave activity.
Anesthesia Research: The tonic inhibitory currents produced by extrasynaptic GABA-A receptor activation are thought to contribute to sedation and anesthetic states. Gaboxadol is used as a tool compound to probe the relative contributions of tonic versus phasic inhibition to anesthetic endpoints.
Neurological and Psychiatric Disorder Models: Dysfunction of extrasynaptic GABA-A receptor-mediated tonic inhibition has been implicated in epilepsy, anxiety disorders, and depression. Gaboxadol is applied in preclinical rodent models to investigate these conditions and evaluate therapeutic hypotheses.
Angelman Syndrome: Research has highlighted the potential relevance of gaboxadol in Angelman syndrome, a neurodevelopmental disorder associated with loss of UBE3A function. Studies in mouse models have explored whether gaboxadol can rescue behavioral and electrophysiological deficits, making it a subject of ongoing investigation in rare disease research.
Handling, Storage, and Preparation Guidelines
Solubility: Gaboxadol hydrochloride is freely soluble in water, facilitating preparation of aqueous stock solutions for in vitro and in vivo applications. The free base form has limited aqueous solubility; researchers should confirm the supplied salt form before preparing solutions.
Storage: Store at room temperature in a tightly sealed container, protected from light and moisture, unless the product datasheet specifies otherwise. For long-term stability, storage at −20 °C is generally recommended. Always refer to the specific product Certificate of Analysis (CoA) for confirmed storage conditions.
Stock Solution Preparation: Dissolve gaboxadol in sterile water or physiological saline (0.9% NaCl) to prepare working stock solutions. Filter-sterilize solutions intended for in vivo administration using a 0.22 µm membrane filter. Prepare aliquots to minimize freeze-thaw cycles.
Safety: Gaboxadol is a centrally active compound with CNS depressant properties. Handle with appropriate personal protective equipment (PPE), including gloves and eye protection. Consult the Safety Data Sheet (SDS) prior to use. Avoid inhalation of dust or aerosols.
Frequently asked questions
What makes gaboxadol different from benzodiazepines as a research tool?
Benzodiazepines are positive allosteric modulators that enhance the effect of endogenous GABA at synaptic GABA-A receptors, primarily those containing γ subunits. Gaboxadol, by contrast, is a direct agonist that selectively activates extrasynaptic GABA-A receptors containing the δ subunit, which mediate tonic inhibition. This selectivity allows researchers to specifically study tonic GABAergic conductances independently of synaptic phasic inhibition, a mechanistic distinction that benzodiazepines cannot provide.
In which animal models is gaboxadol most commonly used?
Gaboxadol is most commonly used in rodent models, including mice and rats. It has been applied in models of sleep and sleep deprivation, epilepsy, anxiety, and neurodevelopmental disorders such as Angelman syndrome mouse models. Its pharmacological selectivity for δ-subunit-containing GABA-A receptors makes it particularly useful in genetic models where these receptor subtypes are manipulated.
What concentration range is typically used for in vitro electrophysiology experiments?
Concentrations typically used to selectively activate extrasynaptic δ-subunit-containing GABA-A receptors in in vitro electrophysiology range from approximately 100 nM to 1 µM, though exact concentrations depend on the specific preparation and experimental objectives. Higher concentrations (>10 µM) may engage additional synaptic receptor subtypes and should be used with caution when selectivity for extrasynaptic receptors is the experimental goal.
Is gaboxadol suitable for in vivo administration in rodents?
Yes, gaboxadol is suitable for in vivo administration in rodents and has been widely used via intraperitoneal (i.p.) and subcutaneous (s.c.) routes in published research. It readily crosses the blood-brain barrier, allowing central pharmacological effects to be achieved after systemic administration. Researchers should consult the literature and institutional animal ethics guidelines to establish appropriate dose ranges for their specific experimental model.
References
- Wafford KA, Ebert B. Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time. Nature Reviews Drug Discovery. 2008;7(6):530-540. doi:10.1038/nrd2464
- Belelli D, Harrison NL, Maguire J, Macdonald RL, Walker MC, Cope DW. Extrasynaptic GABAA receptors: form, pharmacology, and function. Journal of Neuroscience. 2009;29(41):12757-12763. doi:10.1523/JNEUROSCI.3340-09.2009
- Herd MB, Belelli D, Lambert JJ. Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. Pharmacology & Therapeutics. 2007;116(1):20-34. doi:10.1016/j.pharmthera.2007.03.007
- Egawa K, Fukuda A. Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models. Frontiers in Neural Circuits. 2013;7:170. doi:10.3389/fncir.2013.00170
Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
危险品化学品经营许可证（带存储）